...
首页> 外文期刊>Bioscience Reports >The imidazoline derivative calmidazolium inhibits voltage-gated Ca2+-channels and insulin release but has no effect on the phospholipase C system in insulin producing RINm5F-cells
【24h】

The imidazoline derivative calmidazolium inhibits voltage-gated Ca2+-channels and insulin release but has no effect on the phospholipase C system in insulin producing RINm5F-cells

机译:咪唑啉衍生物镇静唑可抑制电压门控的Ca2 +通道和胰岛素释放,但对产生胰岛素的RINm5F细胞中的磷脂酶C系统没有影响

获取原文
           

摘要

The present study shows that the calmodulin antagonist calmidazolium inhibited influx of Ca2+ through voltage-gated Ca2+-channels in clonal insulin producing RINm5F-cells. The mechanism of inhibition may involve both Ca2+-calmodulin-dependent protein kinases and direct binding of calmidazolium to the Ca2+-channel. Calmidazolium did not affect uptake of Ca2+ into intracellular Ca2+-pools, inositol 1,4,5-trisphosphate (InsP3) formation or action on intracellular Ca2+-pools. The calmodulin inhibitor also did not affect glucose utilization or oxidation in RINm5F-cells, speaking against an unspecific toxic effect of the compound. KCl-and ATP-stimulated insulin release from RINm5F-cells was attenuated by calmidazolium, whereas basal hormone secretion was unaffected.
机译:本研究表明,钙调蛋白拮抗剂钙安定唑通过电压门控的Ca2 +通道抑制克隆胰岛素产生的RINm5F细胞中Ca2 +的流入。抑制机制可能涉及Ca2 +-钙调蛋白依赖性蛋白激酶,也包括Calidazolium与Ca2 +-通道的直接结合。 Calmidazolium不会影响Ca2 +进入细胞内Ca2 +池的吸收,肌醇1,4,5-三磷酸(InsP3)的形成或对细胞内Ca2 +池的作用。钙调蛋白抑制剂也没有影响RINm5F细胞中的葡萄糖利用或氧化,表明该化合物具有非特异性的毒性作用。复方丹参酮可减弱RINm5F细胞的KCl和ATP刺激的胰岛素释放,而基础激素的分泌则不受影响。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号